In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 pill to discover safe dosing routine. More participants are going to be enrolled on the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 is going to be given as "increase-on" therapy. https://keeganwkxht.blog-mall.com/32528035/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled